Hereditary tyrosinemia type I is the most severe metabolic disease of the tyrosine catabolic pathway mainly affecting the liver. It is caused by deficiency of fumarylacetoacetate hydrolase, which prevents degradation of the toxic metabolite fumarylacetoacetate (FAA). We report here that FAA induces common effects (i.e., cell cycle arrest and apoptosis) in both human (HepG2) and rodent (Chinese hamster V79) cells, effects that seem to be temporally related. Both the antiproliferative and apoptosis-inducing activities of FAA are dose dependent and enhanced by glutathione (GSH) depletion with L-buthionine-(S,R)-sulfoximine (BSO). Short treatment (2 h) with 35 M FAA/؉BSO or 100 M FAA/؊BSO induced a transient cell cycle arrest at the G2/M transition (20% and 37%, respectively) 24 h post-treatment. In cells treated with 100 M FAA/؊BSO, an inactivation, followed by a rapid over-induction of cyclin B-dependent kinase occurred, which peaked 24 h post-treatment. Maximum levels of caspase-1 and caspase-3 activation were detected at 3 h and 32 h, respectively, whereas release of mitochondrial cytochrome c was maximal at 24 -32 h post-treatment. The G2/M peak declined 24 h later, concomitantly with the appearance of a sub-G1, apoptotic population showing typical nucleosomal-sized DNA fragmentation and reduced mitochondrial transmembrane potential (⌬ m ). These events were prevented by the general caspase inhibitor z-VAD-fmk, whereas G2/M arrest and subsequent apoptosis were abolished by GSH-monoethylester or N-acetylcysteine. Other tyrosine metabolites, maleylacetoacetate and succinylacetone, had no antiproliferative effects and induced only very low levels of apoptosis. These results suggest a modulator role of GSH in FAA-induced cell cycle disturbance and apoptosis where activation of cyclin Bdependent kinase and caspase-1 are early events preceding mitochondrial cytochrome c release, caspase-3 activation, and ⌬ m loss.-Jorquera, R., Tanguay, R. M. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis.
Fumarylacetoacetate (faa) is the metabolite immediately upstream from the hydrolytic reaction catalyzed by fumarylacetoacetate hydrolase (FAH; EC 3.7.1.2), the last enzyme in the tyrosine catabolic pathway (Fig. 1) . Accumulation of FAA ensues the disruption of this hydrolytic step in hereditary tyrosinemia type I (HT I), an autosomal recessive metabolic disease caused by FAH deficiency (McKusick No. 276700) (1) (2) (3) (4) . Severe hepatic alterations are observed in HT I patients, ranging from acute liver dysfunction at early infancy to cirrhosis/hepatocellular carcinoma at mid-childhood (5, 6) . Although the etiopathogenesis of HT I-associated liver pathologies remains unknown, a direct hepatotoxic activity of tyrosine metabolites accumulating in this disease has been suggested but not demonstrated (1, 7, 8) . This hypothesis is based on the fact that FAA and maleylacetoacetate (MAA) possess ␣,␤-unsaturated carbonyl compound structures (see Fig. 1 ) that confer electrophilic properties and potential biological activities. Alkylation of cellular macromolecules such as DNA and/or disruption of essential sulfhydryl reactions by complexation with proteins or glutathione (GSH) are among the mechanisms suggested to underlie the toxic effects of FAA and MAA (1, 8) .
Recently, four studies-two in cultured cells (9, 10) and two in an animal model of HT I (11, 12) -provided evidence supporting the hypothesis that causally links the toxic activity of tyrosine metabolites with HT I-associated liver pathologies. Endo et al. (11) created a double mutant mouse model (FAH Ϫ/Ϫ /HPD Ϫ/Ϫ ) by crossing lethal albino deletion c 14CoS mice, i.e., FAH-deficient mice (13) with mice from a strain lacking p-hydroxyphenylpyruvate dioxygenase (HPD), the enzyme that converts phydroxyphenylpyruvic acid into homogentisic acid (see Fig. 1 ). Although homozygous c 14CoS mice (FAH Ϫ/Ϫ ) die at birth (13) , the homozygous null mutation of the HPD gene in the double mutant can completely rescue the lethal phenotype of FAH deficiency (11) . Retrieval of the tyrosine catabolic pathway in the liver of FAH Ϫ/Ϫ /HPD Ϫ/Ϫ mice by administration of homogentisic acid or by adenovirus-mediated HPD gene transfer resulted in severe acute liver damage, rapid apoptotic death of hepatocytes, and animal death within 16 -30 h after retrieval (11) . These observations led the investigators to suggest a direct relationship between liver injury (induction of apoptosis in hepatocytes) and the accumulation of homogentisic acid-derived metabolites, but without identifying any particular metabolite as inducer of apoptosis. In subsequent work, Kubo et al. (12) proposed that at least one of the signals for cell death in hepatocytes of the double mutant mice was FAA on the basis of the observation that in a cell-free system, cytochrome c was released from mitochondria after the addition of either a cytosolic fraction from the liver of homogentisic acid-treated FAH Ϫ/Ϫ /HPD Ϫ/Ϫ mice or purified FAA from this fraction. In these mice, cytochrome c release occurred prior to apoptotic hepatocyte death and liver failure, and these events could be prevented by caspase inhibitors (12) . However, other than the release of cytochrome c from isolated mitochondria after FAA treatment, this study did not provide direct evidence demonstrating that FAA per se is cytotoxic or an inducer of apoptosis either in vitro or in vivo. In previous studies using cultured cells, we showed that among the tyrosine metabolites that accumulate in HT I, i.e., FAA, MAA, and their derivative succinylacetone (SA), only FAA displayed a mutagenic activity on V79 Chinese hamster lung fibroblasts (9) . Moreover, we demonstrated that FAA was an efficient depletor of cellular glutathione (GSH) and that GSH depletion with L-buthionine-(S,R)-sulfoximine (BSO) enhanced the mutagenicity of FAA (10) .
The present study was therefore performed to extend our knowledge about the intrinsic cytotoxic activity of FAA and to understand the molecular mechanisms that could underlie the toxic effects of FAA in HT I. Since a cytotoxic activity of FAA (i.e., mutagenicity, which we believe to be directly involved in HT I liver pathogenesis) was originally demonstrated in V79 cells (10) , we used this cell line. We show that FAA, unlike MAA and SA, inhibits cell proliferation by arresting the cell cycle in G2/M and that arrested cells then undergo apoptotic death. Similar responses were observed in FAA-treated human HepG2 cells. Among the molecular events that accompany these cytotoxic effects of FAA, activation of cyclin B-dependent kinase and caspase-1 are both early events and precede others such as caspase-3 activation and mitochondrial dysfunction-related events such as cytochrome c release and mitochondrial transmembrane potential (⌬ m ) loss. In addition, we report that as previously observed in our study of the mutagenicity of FAA, both the antiproliferative and apoptosis-inducing activities of FAA are also markedly enhanced by cellular GSH depletion. These cytotoxic activities can be prevented by GSH replenishment agents and caspase inhibitors.
MATERIALS AND METHODS

Chemicals
FAA and MAA were synthesized as described previously (14) and kept frozen at Ϫ80°C until use. SA and BSO were purchased from Sigma Chemical Co. (St. Louis, Mo.). FAA, MAA, SA, or BSO were dissolved in HBSS (GIBCO BRL Products; Grand Island, N.Y.) supplemented with NaHCO 3 (0.35 g/l), pH 7.3. The concentration of FAA or MAA solutions were determined by spectral analysis (14) . All solutions were filter sterilized before treatment of cells.
Cell culture and drug treatments
Chinese hamster V79 cells or human HepG2 cells (ATCC; Rockville, Md.) were grown at 37°C with 5% CO 2 in Dulbec- co's modified Eagle medium (DMEM, high glucose; GIBCO BRL Products) supplemented with 5% or 10%, respectively, fetal bovine serum (FBS; Immunocorp Sciences), and penicillin (100 U/ml)/streptomycin (100 g/ml)/amphotericin B (0.25 g/ml), pH 7.4. Cells were initially seeded at a density of 2.3 ϫ 10 4 cells/ml of medium, which allowed exponential growth at the start of each treatment. For GSH depletion, BSO (0.2 mM) was added to medium 6 h after seeding and left for 18 h. The medium was replaced by HBSS (controls) or HBSS containing FAA, MAA, or SA at the stated concentrations. Treatments were terminated 2 h later by replacing HBSS with fresh medium. When caspase inhibitors or GSH replenishment agents were used, cells were preincubated for 2 h with N-acetyl-Tyr-Val-Ala-Asp-aldehyde (Ac-YVAD-CHO), N-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone (z-DEVD-fmk), or N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk) (Calbiochem; La Jolla, Calif.), GSHmonoethylester (GSH-MEE), or N-acetylcysteine (NAC) (Sigma) before FAA treatment. Cells were harvested at different times post-treatment and processed as indicated below.
Survival and growth studies
Cells were seeded in 6-well plates (Nunc) with 2 ml of medium. The FAA concentration required to achieve 50% cell killing (IC 50 ) was determined 48 h after FAA removal by trypsinization of cells and counting in the presence of 0.1% trypan blue solution, using a hemacytometer. Cell growth was assessed by counting trypan blue-excluding cells from 24 to 96 h post-treatment.
Cell cycle analysis by flow cytometry
Cells were seeded in T-80 flasks (Nunc) with 10 ml of medium. After treatment, floating and trypsinized cells were pooled, centrifuged (1000ϫg for 5 min), resuspended in phosphate-buffered saline (PBS), fixed in cold 70% ethanol, and kept at Ϫ20°C for at least 4 h. Fixed cells (0.5ϫ10 6) were collected by centrifugation (1000ϫg for 10 min) and resuspended in PBS/0.1% Triton X-100 containing RNase (1 mg/ml) and propidium iodide (50 g/ml). Measurement of DNA content of nonapoptotic cells as well as ethanol-extracted low molecular weight DNA from apoptotic cells (sub-G1 population) was done using a Epics Elite Esp flow cytometer (Coulter; Miami, Fla.). The percentage of cells in G1, S, and G2/M phases of the cycle (among nonapoptotic cell population) was calculated using the Multicycleav program (Phoenix Flow Systems Inc.; San Diego, Calif.).
Cell synchronization and detection of apoptosis-associated DNA strand breaks by flow cytometry
Cells were synchronized at the G1/S transition by mimosine treatment (15) . Briefly, cells grown for 24 h in medium were treated with mimosine (200 M) for an additional 18 h period. After release into medium without mimosine, cells progress synchronously through S and G2/M phases. Synchronized cells were treated with FAA (100 Mϫ2 h) either 3.5 h (mid-S) or 6 h (G2/M) after mimosine release. At defined time points after FAA treatment, cells were harvested and prepared for flow cytometry for either DNA content analysis (see above) or in situ TdT assay as described by Gorczyca et al. (16) , using TdT and fluorescein-dUTP (In Situ Cell Death Detection Kit; Boehringer Mannheim; Mannheim, Germany) and simultaneous counterstaining of DNA with propidium iodide.
Detection of apoptosis by fluorescence microscopy and agarose gel electrophoresis
Apoptosis was assessed morphologically by dual staining of cells with the DNA intercalating fluorescent dyes acridine orange and ethidium bromide, which allow simultaneous visualization of the nuclear chromatin pattern and evaluation of cell membrane integrity (17) . After treatment, floating and attached trypsinized cells were pooled, stained (5 g/ml of each dye), mounted, and examined in a fluorescence microscope (Leitz DMRB). The percentages of apoptotic, nonapoptotic, viable, or nonviable cells were determined by analyzing 100 cells/slide. To detect apoptosis-associated internucleosomal DNA fragmentation, low molecular weight DNA from 1 ϫ 10 6 ethanol-fixed cells was extracted as described by Gong et al. (18) , with the addition of a final conventional DNA precipitation step using ammonium acetate 5 M/anhydrous ethanol (0.6/2 v/v). DNA was analyzed by agarose gel electrophoresis (1.5% agarose, 58 V for ϳ2 h) using 0.5ϫ Tris-Borate-EDTA running buffer and visualized by ethidium bromide staining.
Measurement of p34cdc2 kinase activity in immunoprecipitated cyclin B complexes
Cells were seeded in 15 cm Petri dishes (Sarstedt) with 30 ml of medium. At different times post-FAA treatment, cells were harvested by rapidly rinsing twice with cold PBS containing 1 mM PMSF and 0.4 mM Na 3 VO 4 and scraped. The immunoprecipitation procedure was basically as described by Faure et al. (19) , with some minor modifications. Lysis and dilution buffers included EDTA (20 mM)/NaF (50 mM) and NaF (2.5 mM), respectively. Anti-cyclin B (i.e., cyclin B1; 2 g/mg protein; Neomarkers Inc.; Fremont, Calif.) was added to supernatants (200 g protein) and incubated overnight at 4°C. Immunocomplexes were precipitated with 40 l of protein A-Sepharose beads (Sigma) for 2 h at 4°C. The p34cdc2 kinase activity in cyclin B immunoprecipitates was measured using histone H1 as substrate (19) after incubation (10 min at room temperature) of beads in a reaction mixture containing 80 Ci [␥-32 P] ATP (NEN; Boston, Mass.) and 0.1 mg/ml histone H1 (Boehringer Mannheim). Radioactivity was counted on an LKB rack beta counter.
Measurement of caspase-1 and caspase-3 activities
Cytosolic extracts were prepared basically as described by Kluck et al. (20) except the extraction buffer contained 250 mM sucrose. Proteolytic reactions were carried out in extraction buffer (500 l) containing 40 g of cytosolic protein extracts and 160
for assaying caspase-1 or caspase-3 activity, respectively. The reaction mixtures were incubated at room temperature for 4 h and the formation of p-nitroanilide was measured at 405 nm using a Pharmacia LKB Ultrospec III spectrophotometer.
Gel electrophoresis and immunoblotting
For analysis of mitochondrial cytochrome c release and procaspase-3 activation, cytosolic extracts were resuspended in loading buffer [62.5 mM Tris-HCl, pH 6.8, 2.3% sodium dodecyl sulfate (SDS), 10% glycerol, 5% ␤-mercaptoethanol] and proteins (20 g ) were separated by SDS-PAGE (polyacrylamide gel electrophoresis) in a 15% gel. For analysis of cyclin B and MPM-2 protein levels, cells were directly scraped in loading buffer and proteins (20 g) were separated by SDS-PAGE in a 12% gel. After blotting, nitrocellulose membranes were blocked overnight at 4°C with 1% blocking solution (ECL kit; Boehringer Mannheim) and probed with anti-cytochrome c (1/250; monoclonal antibody, clone 7H8.2C12; PharMingen, Ont., Canada), anti-caspase-3 (1/ 1000; polyclonal antibody, p-17 MF393, kindly provided by D. Nicholson, Merck Frosst, Qc, Canada), anti-cyclin B (i.e., cyclin B1; monoclonal antibody, 1/300; Neomarkers Inc.; Fremont, Calif.) or anti-MPM-2 (1/500; monoclonal antibody; Dako Diagnostics Inc., Ont., Canada). An anti-rabbit or anti-mouse immunoglobulin G-horseradish peroxidase was used as secondary conjugated antibody. Signals were revealed using the enhanced chemiluminescence detection system (ECL; Boehringer Mannheim).
Measurement of the mitochondrial transmembrane potential (⌬ m ) by flow cytometry
To measure ⌬ m , the lipophilic dye 3,3Ј-dihexyloxacarbocyanine iodide (DiOC 6 [3] ; Molecular Probes, Inc., Eugene, Oreg.) was used as described by Petit et al. (21) . Briefly, trypsinized cells (2 ϫ 10 5 cells) were rinsed with PBS and incubated with DiOC 6 [3] (0.2 M) for 15 min at 37°C. As a positive control for ⌬ m loss, control cells were sequentially incubated (5 min at 37°C) with the uncoupling agent carbonyl cyanide m-chlorophenylhydrazone (mClCCP, 100 M; Sigma). Fluorescence was measured by flow cytometry using excitation at 488 nm and emission at 525 nm.
RESULTS
FAA is cytotoxic in a dose-and GSH-dependent manner
V79 cells with normal GSH levels or depleted of GSH by BSO pretreatment were exposed to FAA for 2 h and left to recover 48 h in medium. As previously shown, the BSO treatment used here (0.2 mM for 18 h) reduced intracellular GSH contents to 18% of control levels (10) . Figure 2A shows that survival of FAA-treated cells decreased from IC 50 ϭ 65 M to IC 50 ϭ 20 M when treatment was done on GSHdepleted cells. GSH depletion had a marked potentiating effect on FAA-induced cytotoxicity at doses Յ 100 M FAA, but this effect was lost at higher doses. As shown in Fig. 2B , cell proliferation was also inhibited in a dose-dependent manner and GSH depletion prior to FAA treatment potentiated the cell growth inhibitory effects of FAA. Cell recovered rapidly after treatment with 35 M FAA/ϪBSO. In contrast, resumption of cell proliferation was observed only 48 -72 h after treatment with 35 M FAA/ϩBSO and 100 M FAA/ϪBSO or was not observed (100 M FAA/ϩBSO or 200 M FAA/ ϮBSO). Depletion of GSH by BSO treatment did not by itself affect the normal growth of cells (Fig. 2B) . The colony-forming ability of cells treated with 35 M FAA/ϩBSO or 100 M FAA/ϪBSO, as measured 10 days after recovery, was 35% and 15%, respectively, vs. 91% in control cells (data not shown). Neither MAA (100 M) nor SA (1000 M) induced cell toxicity or inhibition of cell proliferation when assayed on normal or BSO-treated cells (data not shown). Thus, both cell survival and proliferation after FAA treatment are dose dependent and susceptible to modulation by manipulating intracellular GSH levels, i.e., GSH depletion decreasing cell survival and proliferation after FAA treatment.
FAA induces cell cycle arrest in exponentially growing cells
To , and 15% (100 M FAA/ϩBSO) vs. 9 -10% in control cells. In cells treated with 100 M FAA/ ϪBSO or 100 M FAA/ϩBSO, a decrease in the G1 population (2N DNA; 22-24% vs. 50 -53% in control cells) and a small sub-G1 peak (Ͻ2N DNA; 10 -13% vs. 0 -2% in control cells) were also observed. The decrease of the G1 peak suggests a block in the progression of G2/M cells to G1, whereas the sub-G1 population is indicative of cell death and is considered to be a marker of apoptosis (22) . The apoptotic death of these cells was confirmed by other methods, such as acridine orange/ethidium bromide staining and the 'DNA ladder' technique (see below). Cells treated with 100 M FAA/ϩBSO also showed an increase in S-phase (63% vs. 38% in control cells) at 24 h post-treatment. This suggests a second block in the cell cycle-inhibition or slowdown of progression through S-phase-which could explain why the G2/M fraction in these cells did not increase to the extent observed after 100 M FAA/ϪBSO treatment. When a shorter recovery interval (e.g., 12 h) was examined, cell cycle alterations were observed only after treatment with 100 M FAA (ϩ/ϪBSO), with the G2/M and sub-G1 peaks being no greater than 12% and the fraction of G1-or S-phase cells moderately decreasing (G1: 35% vs. 51% in controls) or increasing (S: 52% vs. 39% in controls) (data not shown). Treatment with BSO alone did not alter cell cycle progression (Fig. 3A) .
When cells were left to recover 48 h after FAA treatment (Fig. 3B) , a decline in the fraction of cells accumulated in G2/M was observed and was coincident with an increase of the sub-G1 peak. The decrease in G2/M-phase cells was 5% (i.e., from 20% at 24 h to 15% at 48 h) in cells treated with 35 M FAA/ϩBSO and 18% (i.e., from 37% at 24 h to 19% at 48 h) in cells treated with 100 M FAA/ϪBSO. Meanwhile, the decrease in G2/M correlated with the increase in the sub-G1 peak, which was 4% (i.e., from 2% at 24 h to 6% at 48 h) in cells treated with 35 M FAA/ϩBSO and 11% (i.e., from 10% at 24 h to 21% at 48 h) in cells treated with 100 M FAA/ϪBSO. This indicates that a major fraction (ϳ2/3) of FAA-treated cells was arrested in the G2/M-phase before undergoing cell death. In cells treated with 100 M FAA/ϩBSO, the majority of cells were dead at 48 h post-treatment, as indicated by a prominent sub-G1 peak (71%; Fig. 3B , last column). This low DNA content population could be assigned mostly to apoptotic, nonviable cells (dying by a secondary necrosis process), as confirmed by other methods (see below).
Treatment with MAA (100 M) caused a slight decrease in G1-phase (ϪBSO: 44% vs. 50% in controls; ϩBSO: 40% vs. 53% in controls) and an increase in S-phase cells (ϪBSO: 43% vs. 40% in controls; ϩBSO: 49% vs. 38% in controls) at 24 h post-treatment (Fig. 3C , two first panels). However, a normal cell cycle distribution (and proliferation) was found 48 h after MAA treatment (Fig. 3D , two first panels), as similarly observed at any time period after SA (1000 M) treatment (Fig. 3C , D, last two panels).
When human hepatocarcinoma-derived HepG2 cells were treated with FAA (100 M/ϪBSO), cells also accumulated in G2/M (45% vs. 13% in controls) at 24 h post-treatment; the fraction of G2/M-arrested cells declined (from 45% to 24%) at 48 h posttreatment with the concomitant appearance of a sub-G1, apoptotic population (from 22% to 47%; Ͻ 8% in control cells) (data not shown).
In summary, these results show that FAA, but not MAA nor SA, induced sequential G2/M arrest and apoptosis in exponentially growing cells, events that do not seem to be cell type specific. Moreover, the FAA-induced cell cycle arrest and apoptosis are dose and GSH dependent, GSH depletion potentiating these FAA effects.
FAA delays S-phase progression in synchronized cells and arrests cells in G2/M resulting in apoptosis
To better visualize the cell cycle effects of FAA, we synchronized cells at the G1/S boundary by using mimosine (200 Mϫ18 h) (15) . After removal of mimosine, cells progressed synchronously through the cell cycle, reaching the mid-S and G2/M phases 3.5 h and 6 h after mimosine release (Fig.  4A) . At each of these times, synchronous cells were treated with FAA (100 Mϫ2 h), and their cell cycle progression after FAA removal was compared with that of untreated cells by flow cytometric analysis of DNA content. As shown in Fig. 4B , in contrast to control cells that massively entered the subsequent G 1 -phase by 9.5 h after mimosine release (see Fig. 4A ), treatment of cells in mid-S- phase with FAA resulted in a delay in completion of the S-phase, followed by G2/M arrest. Most cells attained a G2/M DNA content by 24 h and remained in G2/M for an extended period (Ͼ32 h). A sub-G1 peak was evident at 32 and 48 h after mimosine release, suggesting that cell death by apoptosis was occurring. As shown in Fig. 4C , similar accumulation of cells with G2/M DNA content and appearance of the sub-G1 peak was observed when synchronous cells were treated in G2/M with FAA. Apoptotic cells were identified by labeling their broken DNA ends with fluoresceindUTP via TdT and simultaneous DNA counterstaining with propidium iodide, which allows identification of their cell cycle position (16) . From the 'contour' graphs shown in Fig. 4B , C, it was clear that apoptosis occurred maximally 32 h after mimosine release in FAA-treated cells whether cells were treated in mid-S or G2/M phases. Moreover, the majority of apoptotic cells were G2/M-phase cells.
Thus, cell cycle disturbance and apoptosis induced by FAA seem to be related events, with accumulation of cells in G2/M preceding their apoptotic death.
Cell death induced by FAA occurs mainly by apoptosis
To quantitatively assess apoptosis and cell viability, exponentially growing cells were treated with FAA and examined at different recovery times by fluorescence microscopy using acridine orange and ethidium bromide. As shown in Fig. 5A , after a 2 h exposure to FAA, only cells treated with 100 M FAA/ϩBSO (0 h, lane 6) showed a low but significant level of apoptosis (8% vs. 2% in controls). Viability (as assessed by ethidium bromide exclusion) of these cells remained high (94%), which is in line with the maintenance of cellular membrane integrity that characterizes (early) apoptosis. Twenty-four hours after FAA treatment, the percentage of apoptotic cells reached 10% for cells treated with 35 M FAA/ϪBSO ( Fig. 5A; 24 h, lane 3) , and ϳ20% for treatments with 35 M FAA/ϩBSO (24 h, lane 4) and 100 M FAA/ϮBSO (24 h, lanes 5 and 6). Apoptotic, nonviable cells (ϳ20%) were observed after treatment with 100 M FAA/ϩBSO ( Fig. 5A ; 24 h, lane 6), which coincided with a fall of cell viability to 87%. At 48 h post-treatment, the percentages of apoptotic, viable cells had increased to 25% and 34% In the latter cells, 8% were apoptotic and nonviable. After a 100 M FAA/ϪBSO treatment (48 h, lane 5), apoptotic, viable cells increased to 54%. In contrast, in cells treated with 100 M FAA/ϩBSO, the percentages of apoptotic, nonviable cells as well as necrotic cells increased, reaching levels of 30% and 14%, respectively ( Fig. 5A ; 48 h, lane 6). As expected, a marked fall in viability (to 77%) was observed in these cells.
Analysis of the DNA isolated from FAA-treated cells by agarose gel electrophoresis confirms the apoptotic death of these cells. Fragmentation of DNA into nucleosome-sized pieces characteristic of apoptosis was barely detectable 24 h after all FAA treatments (data not shown). However, 48 h after the removal of FAA, a substantial fragmentation of DNA into a ladder of nucleosome-sized pieces (ϳ256 bp) occurred in cells treated with 35 M FAA/ϮBSO (Fig. 5B, lanes 3 and 4) and 100 M FAA/ϪBSO (lane 5). The DNA ladder induced by treatment of V79 cells with the apoptosis-inducing agent etoposide (23) is shown for comparison (Fig. 5B, lane 7) . Cells treated with 100 M FAA/ϩBSO showed a DNA 'smear' instead of a DNA ladder (Fig. 5B, lane  6) , likely reflecting the higher levels of necrosis (including apoptotic, nonviable cells) induced by this treatment. Internucleosomal DNA fragmentation was not observed or only barely detectable after treatment with BSO alone (Fig. 5B, lane 2) , MAA (100 M), or SA (1 mM) (data not shown).
In summary, these results show that cell death after FAA treatment occurs mainly by apoptosis and that the extent of FAA-induced apoptosis is dose-and GSH dependent.
FAA causes an early activation of cyclin Bdependent kinase
Since cyclin B-p34cdc2 is a key regulatory complex that controls cell cycle progression from the G2-phase into mitosis (24), we next measured the kinase activity associated with this complex, using histone H1 as substrate. After treatment of asynchronous cells with 100 M FAA/ϪBSO, cell lysates were prepared at different time intervals after FAA removal and immunoprecipitated with anti-cyclin B. Figure 6 shows the relative histone H1 kinase activity of these immunoprecipitates. Immediately after FAA removal, cyclin B-dependent kinase activity was 40% lower than the activity in control cells. The kinase activity gradually recovered, exceeding control values by 10% and 60% at 1 h and 6 h post-treatment, respectively, and reached a maximum 24 h after FAA removal, when it was 3.3-fold higher than control values. For comparison, cells blocked in mitosis with nocodazole had a kinase activity 8 times greater than that of a population of exponentially growing cells (data not shown). The cyclin B-p34cdc2 kinase activity of FAA-treated cells decreased 48 h after treatment, but still showed levels higher (by 80%) than control values. When total cellular levels of cyclin B were analyzed by immunoblotting, FAA-treated cells showed a slight increase in cyclin B protein at 24 -48 h post-treatment (Fig. 7, upper panel) , thus suggesting an accumulation of cyclin B, which occurs late after removal of FAA. Since cyclin B-p34cdc2 kinase is activated at the transition from prophase to metaphase (25), the observed G2/M arrest induced by FAA in the flow cytometric analysis seems to reflect an early mitotic arrest. Twenty-four and 48 h after treatment of cells with 35 M FAA/ϩBSO, the mitotic index was 1% and 4%, respectively, vs. 5% in control cells, whereas no metaphase or postmetaphase figures could be observed in cells treated with 100 M FAA/ϪBSO; however, a mitotic index similar to control cells was observed in these cells 72-96 h after FAA treatment (data not shown). The early mitotic arrest induced by FAA was further confirmed by the strong reactivity of the antibody MPM-2, which reacts with mitosisspecific phosphoproteins (26) and lysates of cells treated with 100 M FAA/ϪBSO, particularly at 24 h post-treatment (Fig. 7, lower panel) .
Thus, these results show that one of the early events induced by FAA is a cell cycle-related event (activation of cyclin B-dependent kinase), and the kinetics of this activation closely follows that of the G2/M arrest.
FAA causes an early activation of caspase-1, followed by mitochondrial cytochrome c release, caspase-3 activation, and a late reduction in ⌬ m
To examine the sequence of molecular events that took place in FAA-induced apoptosis, we simultaneously monitored caspase activity, mitochondrial cytochrome c release, and mitochondrial transmembrane potential (⌬ m ) status at different recovery times after treatment of asynchronous cells with 100 M FAA/ ϪBSO. Caspase-associated proteolytic activities were measured by testing the ability of cytosolic extracts from untreated and FAA-treated cells to cleave the colorimetric peptide substrates YVAD-and DEVD-pNA, correspondingly indicating caspase-1 and caspase-3 activation. As shown in Fig. 8A (upper panel) , caspase-1 activity was already increased 1 h after FAA removal, reached maximal levels (twofold the control values) at 3 h post-treatment, and then declined to control values at 32-48 h post-treatment. Caspase-3 activity was also increased 1 h after FAA treatment, but contrary to caspase-1, its activity remained elevated between 3 and 24 h and then peaked to its maximal level (fivefold the control values) 32 h after FAA treatment (Fig. 8A, lower  panel) . Then the activity of caspase-3 declined, but remained higher than control levels at 48 h posttreatment. A sustained activation of caspase-3 beyond 24 h post-treatment was also confirmed by the decrease of its pro-form by immunoblot analysis (see Fig. 8B , upper panel). The cleavage of PARP, an endogenous substrate for caspases-3 and -7 (27) , also occurred in FAA-treated cells and was maximal at 24 -48 h posttreatment (data not shown).
Cytochrome c protein levels were measured by immunoblot analysis of cytosolic extracts prepared under conditions that keep mitochondria intact. As shown in Fig. 8B (lower panel) , cytochrome c in FAA-treated cells accumulated slightly in the cytosol at 3-6 h post-treatment. However, the release of cytochrome c from mitochondria was maximal 24 -32 h after FAA exposure and lower levels were observed at 48 h post-treatment. Cytochrome oxydase was absent in cytosolic extracts, thus discarding the possibility of mitochondrial contamination (data not shown).
The ⌬ m was monitored in intact cells by fluorescence of the lipophilic dye DiOC 6 [3] , a mitochondrial transmembrane potential-sensitive dye (21) . Compared to untreated cells, no reduction in ⌬ m was observed either before a recovery period of 12 h after FAA treatment (data not shown) or between 12 h and 32 h post-treatment (Fig. 8C) . However, at 48 h after FAA treatment, a population of cells with low ⌬ m was easily observed, thus indicating mitochondrial transmembrane depolarization and dysfunction as usually observed in apoptotic cells. This shift to weaker fluorescence was similar to the decrease in fluorescence observed in cells treated with the mitochondrial uncoupling agent mClCCP.
In summary, caspase-1 activation is an early event in the apoptotic process induced by FAA, whereas the kinetics of caspase-3 activation indicates a late involvement in this process, accompanying cytochrome c release from mitochondria and preceding ⌬ m reduction.
Caspase inhibitors abrogate FAA-induced apoptosis and mitochondrial transmembrane depolarization
To confirm that active caspases are involved in FAA-induced apoptosis, exponentially growing V79 cells were pretreated or not with the caspase inhibitors Ac-YVAD-CHO, z-DEVD-fmk, or z-VAD-fmk before FAA treatment. The specificity of these inhibitors was for caspase-1, caspase-3, and caspase proteases from a broad spectrum, respectively (28, 29) . As shown in Table 1 , all the caspase inhibitors tested reduced or eliminated the fraction of cells dying by apoptosis 48 h after FAA treatment (100 M), as indicated in the FACS analysis by the reduction of the cell population with a sub-G1 DNA content. Both Ac-YVAD-CHO and z-DEVD-fmk were more effective at the highest concentration used (800 M), in contrast to z-VAD-fmk, which already abrogated the sub-G1 peak induced by FAA at a concentration of 100 M. Similar results were obtained by preincubating cell with the serine protease inhibitor TLCK (data not shown). The caspase inhibitor z-VAD-fmk was used to test the possibility that active caspases may induce the reduction in ⌬ m observed in the apoptotic cell population after FAA treatment. As shown in Fig. 9 , preincubation of cells with z-VAD-fmk (100 Mϫ2 h) markedly reduced the loss of ⌬ m induced by FAA at 48 h posttreatment. Thus, active caspases are involved in the cell death process induced by FAA; they impinge on mitochondria to induce mitochondrial permeability transition and a subsequent loss in ⌬ m during FAA-induced apoptosis.
GSH-monoethylester or N-acetylcysteine abrogate FAA-induced apoptosis
Since both the extent of G2/M arrest and subsequent apoptosis induced by FAA appeared to be GSH dependent, we investigated whether these effects of FAA could be modulated by GSH replenishment agents such as GSH-MEE or NAC. Exponentially growing cells were preincubated with these agents at different concentrations for 2 h and then treated with FAA. As shown in Table 2 , both GSH-MEE and NAC markedly reduced the accumulation of cells in G2/M induced by FAA at 24 h posttreatment and the sub-G1 peak associated with apoptosis at 48 h post-treatment. These effects were observed at the highest concentration of GSH-MEE (20 mM) or NAC (1 mM) used. Similar effects were obtained by treating cells concomitantly with FAA and GSH (1 mM), but not when GSH was added immediately after FAA treatment (data not shown). Thus, GSH has a protective role on cell cycle distur- Figure 8 . FAA causes an early activation of caspase-1, followed by mitochondrial cytochromec release, caspase-3 activation, and a late mitochondrial transmembrane depolarization. V79 cells were harvested at the indicated recovery periods after FAA treatment (100 Mϫ2 h). Cytosolic extracts were used for evaluation of caspase-1 and caspase-3 activation using the colorimetric substrate YVAD-pNA and DEVD-pNA, respectively (A); whole cell lysates were used for immunoblot analysis of caspase-3 and cytochromec protein levels (B). The caspase activity of untreated cells shown in panel A is represented by a line at 100%. Measurement of the mitochondrial transmembrane potential (⌬ m ) was done on intact cells by DiOC 6 [3] staining and flow cytometry (C). Cells treated with the uncoupling agent mClCCP were used as a positive control for ⌬ m loss. bance and apoptosis induced by FAA, effects that seem to result from a direct conjugation activity of GSH on FAA.
DISCUSSION
We previously reported that FAA is mutagenic in V79 cells and that depletion of intracellular GSH can enhance the mutagenic activity of FAA (10) . The present study shows that FAA is cytotoxic in a doseand GSH-dependent manner and that FAA-induced cytotoxicity 1) correlates with cell cycle arrest at G2/M and 2) occurs through an apoptotic pathway. The sequence of molecular events that occur between the end of FAA treatment, the cell cycle arrest at the G2/M transition at 24 h post-treatment, and the late manifestation of apoptotic cell death (digestion of genomic DNA at 48 h post-treatment) may be ordered as early events, which include caspase-1 and cyclin B-dependent kinase activation, and late events, which include cytochrome c release, caspase-3 activation, and ⌬ m reduction.
The present data are consistent with the recent observation by Kubo et al. (12) that FAA induces the release of cytochrome c from mitochondria in a cellfree system, but they do not support the hypothesis proposed by these investigators that the FAA-induced cytochrome c release from mitochondria as an initial event by itself triggers the activation of the apoptotic caspase cascade involving caspases-1 and -3. These investigators showed the overall involvement of caspases-1 and -3 in apoptosis induced by homogentisic acid in FAH Ϫ/Ϫ /HPD Ϫ/Ϫ hepatocytes or mice, but without directly assaying FAA in their experiments. Assuming that FAA was the homogentisic acid-derived metabolite responsible for caspase activation in the study by Kubo et al. (12) , our kinetic data point instead to a role of caspase-1 activation, which peaks early (3 h) post-treatment, in the upstream phase of apoptosis induced by FAA, prior to cytochrome c release and mitochondrial dysfunction. Activated caspase-1 may function as the activator of downstream caspase-3, as already shown, for example, in glucocorticoid-treated human T cells undergoing apoptosis (30) . Certainly, a fraction of FAA may attack the mitochondria directly, causing cytochrome c release and subsequent activation of a caspase cascade, but according to recent work by Slee et al. (31) , this cascade would not involve caspase-1 activation. These investigators demonstrated that cytochrome c in cytosol can activate through caspase-9 activation the effector caspase-7 or initiate the hierarchical activation of caspase-3 as well as caspases-2, -6, -8, and -10, activation of the latter caspases being dependent on caspase-3 activation. Apaf-1, a cytosolic factor, is required for this cytochrome c/caspase-3-dependent caspase cascade, which excludes the ICE subfamily caspases (caspases-1, -4, and -5) (31) .
The release of cytochrome c from mitochondria into the cytosol and other mitochondrial changes may play a central role in the regulation and activation of the executioner phase of apoptosis induced by FAA. This is supported by the fact that the kinetics of cytochrome c release closely follows that of caspase-3 activation, both events peaking relatively late in the death process (at 24 and 32 h posttreatment, respectively) and preceding the time of genomic DNA fragmentation. The dependency of the executioner phase of apoptosis, which includes caspase-3 activation, on cytochrome c release from mitochondria has been demonstrated in other studies (32, 33) . Since a reduction in ⌬ m was observed a The percentage of apoptotic cells (sub-G1 population) and the percentage of cells in G1, S, and G2/M phases of the cycle (among the nonapoptotic cell population) were estimated based on DNA staining with propidium iodide. Cells were incubated with different concentrations of caspase inhibitors for 2 h before treatment with FAA (100 Mϫ2 h). After FAA treatment, cells were left to recover in fresh medium for 48 h and then harvested and processed for flow cytometric analysis of DNA content as described in Materials and Methods. Cell cycle distribution of control, untreated cells is G1, 50%; S, 40%; and G2/M, 10%, with a sub-G1 population of 2%.
only late (at 48 h post-treatment) in the apoptotic process induced by FAA, it seems that cytochrome c is released from coupled mitochondria. In fact, the breakdown in ⌬ m , which indicates mitochondrial dysfunction, was not found until the time of DNA fragmentation, well after the first morphological evidence of apoptosis obtained by fluorescence microscopy. Thus, mitochondrial transmembrane depolarization is not a critical step in the commitment of cells to die after FAA treatment. Instead, mitochondrial dysfunction seems to reflect rather than predict the apoptotic death of cells treated with FAA. A late decrease in ⌬ m either during or after DNA fragmentation has been observed in other situations, such as after UVB irradiation or staurosporine treatment of CEM or HeLa cells, or in nerve growth factor-deprived neurons (34, 35) . Certainly, the block of FAA-induced ⌬ m reduction after preincubation of cells with the general caspase inhibitor z-VAD-fmk may be due to a primary action of this inhibitor on upstream caspases such as caspase-8 (36) . However, the involvement of early caspase activation events other than caspase-1 or that of other apoptosis-transducing signals in the upstream phase of the apoptotic process induced, directly or indirectly, by FAA remains to be elucidated.
The early induction by FAA of cyclin B-p34cdc2 kinase activity, whose peak correlated with maximal accumulation of cells in G2/M, and the sequential apoptotic death of G2/M-arrested cells suggest the involvement of cell cycle-related events in FAA-induced apoptosis. Both cell cycle arrest and cyclindependent kinase activation have been demonstrated to occur and to be a requisite step in several, but not all, instances of apoptotic cell death. This requirement was observed in the apoptotic pathway induced by the glucocorticoid dexamethasone or APO-1(Fas/CD95), which involves serial activation of ICE-related caspases and caspase-3, or by granzyme B, a direct activator of caspase-3 (30, 37, 38) . However, in all these cases the molecular signaling process that links cell cycle-related events with apoptosis remains unclear. Unscheduled or premature activation of cyclin B-p34cdc2 kinase leading to apoptosis has been observed after treatment of cells with agents known to damage DNA, such as cisplatin or etoposide (39, 40) . Another DNA-damaging agent, nitrogen mustard, has been shown to hyperactivate cyclin B-p34cdc2 kinase after its initial and transient inactivation (41) . Similar sequential events were observed after FAA treatment of cells. The relatively high levels of cyclin B-p34cdc2 kinase activity observed 48 h after FAA treatment may reflect the slight accumulation of cyclin B observed at this time, but whether this results from increased synthesis of cyclin B or inhibition of its degradation was not examined. Although we have not yet been able to demonstrate that FAA directly damages DNA, its mutagenic activity in V79 cells (10) supports its action on DNA. Activation of the G2/M transition checkpoint is a common mechanism by which cells a The percentage of apoptotic cells (sub-G1 population) and the percentage of cells in G1, S, and G2/M phases of the cycle (among the nonapoptotic cell population) were estimated based on DNA staining with propidium iodide. Cells were incubated with different concentrations of GSH replenishment agents for 2 h before treatment with FAA (100 Mϫ2 h). After FAA treatment, cells were left to recover in fresh medium for 24 or 48 h, then harvested and processed for flow cytometric analysis of DNA content as described in Materials and Methods. Cell cycle distribution of control, untreated cells is G1, 50%; S, 40%; and G2/M, 10%, with a sub-G1 population of 2%.
respond to genotoxic stress. The resulting G2/M arrest is thought to allow repair of DNA damage prior to cell division and ensure that DNA replication will proceed with fidelity to avoid segregation of defective chromosomes and potential tumorigenesis (42) . The specific tyrosine phosphatase cdc25C involved in the activation of p34cdc2 has been identified as one main target of the DNA damage checkpoint (43, 44) . However, as reported recently, it seems that multiple pathways may be involved in initiating the G2/M checkpoint and modulating cyclin B-p34cdc2 kinase activity depending on types of DNA damage (45) . Which types of DNA damage or G2/M checkpoint pathway are induced by FAA remains to be determined.
Cellular GSH levels seem to modulate the cytotoxic effects of FAA (G2/M arrest and apoptosis) in a manner similar to that previously suggested for its mutagenicity, that is, through a buffering-like activity (10) . This means that the greater the free/effective FAA dose that depends directly on the amount of cellular GSH available for FAA conjugation, the greater the cytotoxicity of FAA. This mechanism is suggested by the similarities between the cytotoxic/ cytostatic effects induced by a relative low dose of FAA (35 M) with BSO pretreatment and by a high dose of FAA (100 M) without BSO pretreatment. A direct conjugation activity of GSH on FAA is also supported by the fact that the addition to cells of free GSH concomitantly with FAA abrogates the cytotoxic/cytostatic effects of FAA (R. Jorquera and R. M. Tanguay, unpublished observations). However, there is also the possibility that FAA-induced apoptosis could be mediated by a GSH-dependent process. A similar potentiating effect of cellular GSH depletion on apoptosis induction has been reported in cells treated with diamide, a thioloxidant agent (46) . In this situation, the effective dose of diamide necessary to induce apoptosis and related events, such as mitochondrial cytochrome c release and caspase-3 activation, was markedly reduced in BSO-pretreated cells. Other reports demonstrate that GSH or other thiol-reducing agents may influence the apoptotic response through, for example, its participation in the redox regulation of caspase-3 activity (46, 47) . At the dose used here (0.2 mM), BSO per se (i.e., GSH depletion) does not have cytotoxic effects or alter cell growth or cell cycle progression. Moreover, it has been reported that preculture of human cells with BSO (5 mM) itself caused neither the induction of apoptosis nor activation of caspase-3 (46) . The requirement of maintenance of a cellular reducing environment for counteracting the cytotoxic/cytostatic effects of FAA is well demonstrated in our study by the beneficial action of preincubating cells with GSH-MEE or NAC. In this case, both cell cycle block and apoptosis induced by FAA are abrogated. We believe that these agents exert their anti-apoptotic effect through their GSH replenishment activity rather than by acting as ROS scavengers, since we have previously shown that ROS are not generated in FAA-treated cells (10) .
Taken together, our previous (10) and present results show dual but opposite activities of FAA as far as the cancer induction process is concerned. On one side, FAA has a mutagenic activity that could be involved in the initiation of the carcinogenic process in the liver of HT I patients. On the other hand, FAA induces apoptosis, which in theory should help to eliminate mutated cells. However, this cytotoxic activity of FAA may trigger a regenerative process in the liver and, after multiple, chronic rounds of hepatocyte loss/proliferation, contribute to cirrhosis establishment, which may favor fixation of oncogenic mutations. Through its mutagenic activity or via a metabolic effect, FAA may target genes or proteins essential for defense mechanisms such as DNA repair. A recent study has shown that SA, a derivative of FAA which accumulate in HT I, has an inhibitory activity on DNA-ligase, a DNA repair enzyme. Moreover, the activity of this enzyme was found to be low in HT I fibroblasts (48) . In line with these observations, we have previously suggested (10) that FAA, through its GSH-depleting activity, could impair DNA repair processes, as reported to occur in human cells with low GSH levels due to a genetic deficiency in GSH synthetase (49) . Thus, abnormal DNA repair in HT I patients could predispose them to cancer induction, where FAA acts as an hepatocarcinogen. Although the risk of hepatocellular carcinoma such as that occurring in 'chronic' HT I could be decreased by therapeutically increasing the level of apoptotic death of hepatocytes, the risk of hepatic dysfunction, such as occurs in 'acute' HT I, might also increase. Thus, we believe that any potential HT I therapy focused to manipulate the apoptotic process in the liver should be postponed until the identification of molecular/biochemical markers that will render the pathophysiological manifestations of the disease more predictable.
